Article Text

Download PDFPDF

Rationale for and design of the Idiopathic Pulmonary Fibrosis–PRospective Outcomes (IPF-PRO) registry
  1. Emily C O'Brien1,
  2. Michael T Durheim1,
  3. Victoria Gamerman2,
  4. Sandy Garfinkel3,
  5. Kevin J Anstrom4,
  6. Scott M Palmer1 and
  7. Craig S Conoscenti5
  1. 1Department of Medicine, Duke University, Duke Clinical Research Institute, Durham, North Carolina, USA
  2. 2Biometrics and Data Management, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, Connecticut, USA
  3. 3Clinical Operations, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, Connecticut, USA
  4. 4Department of Biostatistics and Bioinformatics, Duke Clinical Research Institute, Durham, North Carolina, USA
  5. 5Clinical Development and Medical Affairs, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, Connecticut, USA
  1. Correspondence to Dr Emily C O'Brien; emily.obrien{at}duke.edu

Abstract

Background Idiopathic pulmonary fibrosis (IPF) is a chronic interstitial lung disease characterised by progressive loss of lung function. Its clinical course is variable but ultimately fatal. There is a need for a multicentre patient registry incorporating longitudinal clinical data and biological samples to improve understanding of the natural history of IPF and contemporary practice patterns.

Methods/design The Idiopathic Pulmonary Fibrosis–PRospective Outcomes (IPF-PRO) registry is a national IPF registry in the USA. This registry will enrol approximately 300 patients with newly diagnosed IPF over 2 years at approximately 14 tertiary pulmonary care sites. Participants will be followed for 3–5 years and will receive usual care, as defined by their physician. Clinical data from the year prior to diagnosis will be collected from medical record review on enrolment. Subsequently, data on diagnostic evaluations, pulmonary function tests, physical examinations, laboratory data and clinical events will be collected at routine clinical visits and via a call centre. Participants will complete patient-reported outcome questionnaires at enrolment and then at approximately 6-month intervals. Blood samples for cellular, genetic and transcriptomic analyses will be collected at the same intervals.

Results The first results from the IPF-PRO registry will be presented in 2015.

Conclusions The IPF-PRO registry will improve understanding of the natural history of IPF, its impact on patients and current practice in the diagnosis and care of patients with IPF. The registry will establish a repository of biological samples from a well-characterised patient population for future research.

Clinical trial number NCT01915511.

  • Interstitial Fibrosis
  • Rare lung diseases

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.